Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Baxter/Vimrx

This article was originally published in The Gray Sheet

Executive Summary

Baxter/Vimrx: Firms ink definitive agreement whereby Vimrx Pharmaceuticals and Baxter's Immunotherapy Division will merge to create a new cell therapy company to market cell selection systems, such as Baxter's Isolex 300SA -- a premarket approval application for which currently is pending at FDA -- and Baxter's Isolex 300i. Both systems are marketed in Europe. As outlined in the firms' June 12 letter of intent ("The Gray Sheet" June 16, I&W-7), Vimrx will control 85% of the new entity in exchange for convertible preferred shares with a nominal value of $40 mil. and 11 mil. Vimrx common shares. Baxter will contribute $30 mil. to the company for initial operating funds, a figure $10 mil. larger than the amount Baxter had reported in June. As previously announced, Vimrx will provide $10 mil. in initial funding for the company...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT008975

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel